Inozyme Pharma's market cap is currently ―. The company's EPS TTM is $-1.387; its P/E ratio is -3.39; Inozyme Pharma is scheduled to report earnings on May 7, 2024, and the estimated EPS forecast is $-0.36. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
EBIT	$ -18.21M	$ -16.64M	$ -15.58M	$ -17.40M	$ -19.36M
EBITDA	$ -19.90M	$ -17.73M	$ -16.32M	$ -17.86M	$ -19.75M
Net Income Common Stockholders	$ -21.54M	$ -16.64M	$ -15.58M	$ -17.40M	$ -18.54M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 188.59M	$ 192.44M	$ 140.25M	$ 130.93M	$ 127.87M
Total Assets	$ 200.85M	$ 205.70M	$ 150.93M	$ 141.80M	$ 139.19M
Total Debt	$ 46.59M	$ 34.10M	$ 34.12M	$ 26.66M	$ 6.78M
Net Debt	$ -142.00M	$ -158.34M	$ -106.13M	$ -104.27M	$ -121.09M
Total Liabilities	$ 60.37M	$ 45.49M	$ 45.34M	$ 38.45M	$ 20.80M
Stockholders Equity	$ 140.48M	$ 160.21M	$ 105.64M	$ 103.35M	$ 118.39M
Cash Flow	-
Free Cash Flow	$ -18.59M	$ -18.88M	$ -15.56M	$ -17.95M	$ -14.45M
Operating Cash Flow	$ -18.49M	$ -18.87M	$ -15.55M	$ -17.77M	$ -14.40M
Investing Cash Flow	$ -6.47M	$ -44.62M	$ -16.33M	$ 13.77M	$ 3.22M
Financing Cash Flow	$ 12.52M	$ 69.72M	$ 23.64M	$ 20.10M	-

Currency in USD

Inozyme Pharma Earnings and Revenue History

Income Statement >

Inozyme Pharma Debt to Assets

Balance Sheet >

Inozyme Pharma Cash Flow

Cash Flow >

Inozyme Pharma Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing